India Oncology NGS Market Size, Share & Trends Analysis Report By End-use (Clinical Research, Hospitals & Clinics), By Technology, By Application, By Product & Service, By Workflow, And Segment Forecasts, 2023

The India oncology NGS market size is expected to reach USD 85.7 million by 2030, registering a CAGR of 17.4% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The development of companion diagnostic assays for personalized medicine, growing adoption of sequencing platforms for cancer diagnosis, and increasing investment for the development of genomic databases are the key driving factors for market growth.

The increasing need for user-friendly sequencing workflows along with cost-effective solutions contribute to the rising adoption rate of this technology in India. The availability of the genome database for the Indian population eases the process of developing companion diagnostics & personalized medicine and offers access to stratified samples for the research. In addition, a rise in cancer incidence in India is expected to be a high impact rendering driver of the market. For instance, the WHO states that 851,678 deaths and over 1,324,413 cancer cases were registered in 2020 in India.

The COVID-19 pandemic had a cascading effect on the supply chain of next-generation sequencing and delayed various sequencing projects. For instance, Illumina experienced a shortfall in the supply of reagents' raw materials and caused delays in reagents delivery by weeks, which is usually in days. Similarly, various Next Generation Sequencing (NGS)resources were pulled out from oncology development to the COVID-19 study.

Next-generation sequencing technology was able to screen multiple samples and identify the virus without prior inputs of the infection. It was further used for surveillance and epidemiological studies. Although oncology NGS was not a very active segment in COVID-19, the overall demand for NGS products will affect the price level in the market.

India Oncology NGS Market Report Highlights:

The targeted & gene panel sequencing segment held the major market share in 2022 as targeted panels offer economical solutions for providing actionable and clear information to the physicians
The research studies segment occupied a major share of the applications in 2022 owing to the increasing usage of NGS technology for oncology research in India
The diagnostics and screening segment is anticipated to grow at the fastest CAGR from 2023 to 2030 owing to increasing recommendations for oncology screening and the high adoption rate of NGS-based molecular diagnosis of cancer
The platforms and related products segment are expected to account for the maximum revenue share by 2030. Ongoing research to evaluate the performance of various targeted NGS gene panels regarding their technical features and clinical utility is driving the adoption rate in this segment
The sequencing segment led the market in 2020 and is estimated to expand further at the fastest growth rate from 2023 to 2030 as it is the most critical phase in the workflow
The clinical research segment is expected to grow at the fastest CAGR from 2023 to 2030 owing to the use of NGS in cancer research and, more specifically, in the discovery of new cancer-related genes, studying tumor heterogeneity, and identification of alterations that contribute to tumorigenesis
The Indian market is marked by the presence of distributors of global leaders. For instance, Premas Life Sciences Pvt. Ltd. is a registered distributor of Illumina in India. Premas Life Sciences Pvt. Ltd. and Medgenome Labs are two of the largest players in the Indian market

Product Code: GVR-4-68039-217-3

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Product & service
- 1.1.2. Technology
- 1.1.3. Application
- 1.1.4. Workflow
- 1.1.5. End use
- 1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Product & service outlook
- 2.2.2. Technology outlook
- 2.2.3. Application outlook
- 2.2.4. Workflow outlook
- 2.2.5. End use outlook
2.3. Competitive Insights

Chapter 3. India Oncology NGS Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
3.4. India Oncology NGS Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
  - 3.4.1.1. Supplier power
  - 3.4.1.2. Buyer power
  - 3.4.1.3. Substitution threat
  - 3.4.1.4. Threat of new entrant
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Technological landscape
  - 3.4.2.3. Economic landscape

Chapter 4. India oncology NGS: Product & Service Estimates & Trend Analysis

4.1. India Oncology NGS Market: Key Takeaways
4.2. India Oncology NGS: Movement & Market Share Analysis, 2022 & 2030
4.3. Platforms and Related Products
- 4.3.1. Platforms and related products market estimates and forecasts, 2018 to 2030 (USD Million)
  - 4.3.1.1. Panels
  - 4.3.1.2. Panels market estimates and forecasts, 2018 to 2030 (USD Million)
  - 4.3.1.3. Consumables
  - 4.3.1.4. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
  - 4.3.1.5. Platforms
  - 4.3.1.6. Platforms market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Services
- 4.4.1. services market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. India oncology NGS: Technology Estimates & Trend Analysis

5.1. India oncology NGS Market: Key Takeaways
5.2. India oncology NGS: Movement & Market Share Analysis, 2022 & 2030
5.3. Whole Genome Sequencing
- 5.3.1. Whole genome sequence market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Whole Exome Sequencing
- 5.4.1. Whole exome sequence market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Targeted & Gene Panel Sequencing
- 5.5.1. Targeted & gene panel sequence market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.2. Amplicon-based
  - 5.5.2.1. Amplicon-based sequence market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.3. Hybridization-based
  - 5.5.3.1. Hybridization-based sequence market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. India oncology NGS: Application Estimates & Trend Analysis

6.1. India Oncology NGS Market: Key Takeaways
6.2. India Oncology NGS: Movement & Market Share Analysis, 2022 & 2030
6.3. Diagnostics and Screening
- 6.3.1. Diagnostics and screen market estimates and forecasts, 2018 to 2030 (USD Million)
  - 6.3.1.1. Screening
  - 6.3.1.1.1. Screen market estimates and forecasts, 2018 to 2030 (USD Million)
  - 6.3.1.1.2. Sporadic Cancer Screening
  - 6.3.1.1.2.1. Sporadic cancer screen market estimates and forecasts, 2018 to 2030 (USD Million)
  - 6.3.1.1.3. Inherited Cancer Screening
  - 6.3.1.1.3.1. Inherited cancer screen market estimates and forecasts, 2018 to 2030 (USD Million)
  - 6.3.1.2. Companion Diagnostics (CDX)
  - 6.3.1.2.1. Companion diagnostics (CDX)market estimates and forecasts, 2018 to 2030 (USD Million)
  - 6.3.1.3. Other Diagnostics
  - 6.3.1.3.1. Other diagnostics estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Research Studies
- 6.4.1. Research studies diagnostics estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. India oncology NGS: Workflow Estimates & Trend Analysis

7.1. India Oncology NGS Market: Key Takeaways
7.2. India Oncology NGS: Movement & Market Share Analysis, 2022 & 2030
7.3. Pre-Sequencing
- 7.3.1. Pre-Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.3.1.1. NGS Library Preparation Kits
  - 7.3.1.2. NGS Library Preparation Kits market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.3.1.3. Semi-Automated Library Preparation
  - 7.3.1.4. Semi-automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.3.1.5. Automated Library Preparation
  - 7.3.1.6. Automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.3.1.7. Clonal Amplification
  - 7.3.1.8. Clonal amplification market estimates and forecast, 2018 - 2030 (USD Million)
7.4. Sequencing
- 7.4.1. Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
7.5. NGS Data Analysis
- 7.5.1. NGS Data Analysis market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.5.1.1.1. NGS primary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.5.1.2. NGS Secondary Data Analysis
  - 7.5.1.2.1. NGS secondary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
  - 7.5.1.3. NGS Tertiary Data Analysis
  - 7.5.1.3.1. NGS tertiary data analysis market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. India oncology NGS: End-Use Estimates & Trend Analysis

8.1. India Oncology NGS Market: Key Takeaways
8.2. India Oncology NGS: Movement & Market Share Analysis, 2022 & 2030
8.3. Academic Research
- 8.3.1. Academic research market estimates and forecast, 2018 - 2030 (USD Million)
8.4. Clinical Research
- 8.4.1. Clinical research market estimates and forecast, 2018 - 2030 (USD Million)
8.5. Hospitals and Clinics
- 8.5.1. Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
8.6. Pharma & Biotech Entities
- 8.6.1. Pharma & biotech entities market estimates and forecast, 2018 - 2030 (USD Million)
8.7. Other Users
- 8.7.1. Other users market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
- 9.2.1. Illumina, Inc.
  - 9.2.1.1. Company overview
  - 9.2.1.2. Financial performance
  - 9.2.1.3. Product benchmarking
  - 9.2.1.4. Strategic initiatives
- 9.2.2. Genotypic Technology Pvt Ltd.
  - 9.2.2.1. Company overview
  - 9.2.2.2. Financial performance
  - 9.2.2.3. Product benchmarking
  - 9.2.2.4. Strategic initiatives
- 9.2.3. Tecan Trading AG
  - 9.2.3.1. Company overview
  - 9.2.3.2. Financial performance
  - 9.2.3.3. Product benchmarking
  - 9.2.3.4. Strategic initiatives
- 9.2.4. Xcelris Genomics
  - 9.2.4.1. Company overview
  - 9.2.4.2. Financial performance
  - 9.2.4.3. Product benchmarking
  - 9.2.4.4. Strategic initiatives
- 9.2.5. Eurofins Scientific
  - 9.2.5.1. Company overview
  - 9.2.5.2. Financial performance
  - 9.2.5.3. Product benchmarking
  - 9.2.5.4. Strategic initiatives
- 9.2.6. 4baseCare
  - 9.2.6.1. Company overview
  - 9.2.6.2. Financial performance
  - 9.2.6.3. Product benchmarking
  - 9.2.6.4. Strategic initiatives
- 9.2.7. MedGenome
  - 9.2.7.1. Company overview
  - 9.2.7.2. Financial performance
  - 9.2.7.3. Product benchmarking
  - 9.2.7.4. Strategic initiatives
- 9.2.8. Sayre Therapeutics
  - 9.2.8.1. Company overview
  - 9.2.8.2. Financial performance
  - 9.2.8.3. Product benchmarking
  - 9.2.8.4. Strategic initiatives
- 9.2.9. Redcliffe Lifesciences
  - 9.2.9.1. Company overview
  - 9.2.9.2. Financial performance
  - 9.2.9.3. Product benchmarking
  - 9.2.9.4. Strategic initiatives
- 9.2.10. Partek Inc.
  - 9.2.10.1. Company overview
  - 9.2.10.2. Financial performance
  - 9.2.10.3. Product benchmarking
  - 9.2.10.4. Strategic initiatives
- 9.2.11. Bio-Rad Laboratories
  - 9.2.11.1. Company overview
  - 9.2.11.2. Financial performance
  - 9.2.11.3. Product benchmarking
  - 9.2.11.4. Strategic initiatives
- 9.2.12. Myriad Genetics
  - 9.2.12.1. Company overview
  - 9.2.12.2. Financial performance
  - 9.2.12.3. Product benchmarking
  - 9.2.12.4. Strategic initiatives
- 9.2.13. Hologic, Inc. (Gen-Probe Inc.)
  - 9.2.13.1. Company overview
  - 9.2.13.2. Financial performance
  - 9.2.13.3. Product benchmarking
  - 9.2.13.4. Strategic initiatives
- 9.2.14. Perkin Elmer, IncVela Diagnostics
  - 9.2.14.1. Company overview
  - 9.2.14.2. Financial performance
  - 9.2.14.3. Product benchmarking
  - 9.2.14.4. Strategic initiatives
- 9.2.15. Premas Life Sciences Pvt Ltd (PLS)
  - 9.2.15.1. Company overview
  - 9.2.15.2. Financial performance
  - 9.2.15.3. Product benchmarking

Product Code: GVR-4-68039-217-3

List of Tables

Table 1 List of abbreviation
Table 2 India oncology NGS market, by product & service, 2018 - 2030 (USD Million)
Table 3 India oncology NGS market, by technology, 2018 - 2030 (USD Million)
Table 4 India oncology NGS market, by application, 2018 - 2030 (USD Million)
Table 5 India oncology NGS market, by workflow, 2018 - 2030 (USD Million)
Table 6 India oncology NGS market, by end use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 India oncology NGS: Market outlook
Fig. 9 India oncology NGS: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 India oncology NGS market driver impact
Fig. 15 India oncology NGS market restraint impact
Fig. 16 India oncology NGS market strategic initiatives analysis
Fig. 17 India oncology NGS market: Product & service movement analysis
Fig. 18 India oncology NGS market: Product & service outlook and key takeaways
Fig. 19 Platforms and related products market estimates and forecasts, 2018 - 2030
Fig. 20 Panels market estimates and forecasts, 2018 - 2030
Fig. 21 Consumables market estimates and forecasts, 2018 - 2030
Fig. 22 Platforms market estimates and forecasts, 2018 - 2030
Fig. 23 Services market estimates and forecasts, 2018 - 2030
Fig. 24 India oncology NGS market: Technology movement analysis
Fig. 25 India oncology NGS market: Technology outlook and key takeaways
Fig. 26 Whole genome sequencing market estimates and forecasts, 2018 - 2030
Fig. 27 Whole exome sequencing market estimates and forecasts, 2018 - 2030
Fig. 28 Targeted & gene panel sequencing market estimates and forecasts, 2018 - 2030
Fig. 29 Amplicon-based market estimates and forecasts, 2018 - 2030
Fig. 30 Hybridization-based market estimates and forecasts, 2018 - 2030
Fig. 31 India oncology NGS market: Application movement analysis
Fig. 32 India oncology NGS market: Application outlook and key takeaways
Fig. 33 Diagnostic and screening market estimates and forecasts, 2018 - 2030
Fig. 34 Screening market estimates and forecasts, 2018 - 2030
Fig. 35 Companion diagnostics market estimates and forecasts, 2018 - 2030
Fig. 36 Others diagnostics market estimates and forecasts, 2018 - 2030
Fig. 37 Research studies market estimates and forecasts, 2018 - 2030
Fig. 38 India oncology NGS market: Workflow outlook and key takeaways
Fig. 39 India oncology NGS market: Workflow outlook and key takeaway
Fig. 40 Pre-sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 NGS library preparation kits market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Semi-automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Automated library preparation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Clonal amplification market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 NGS Data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 NGS primary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 NGS secondary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 NGS tertiary data analysis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 India oncology NGS market: End-use outlook and key takeaways
Fig. 51 India oncology NGS market: End-use outlook and key takeaway
Fig. 52 Academic Research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Clinical Research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Pharma & Biotech Entities market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Other users market estimates and forecast, 2018 - 2030 (USD Million)

India Oncology NGS Market Size, Share & Trends Analysis Report By End-use (Clinical Research, Hospitals & Clinics), By Technology, By Application, By Product & Service, By Workflow, And Segment Forecasts, 2023 - 2030

Description

Table of Contents

List of Tables

India Oncology NGS Market Growth & Trends:

India Oncology NGS Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. India Oncology NGS Variables, Trends & Scope

Chapter 4. India oncology NGS: Product & Service Estimates & Trend Analysis

Chapter 5. India oncology NGS: Technology Estimates & Trend Analysis

Chapter 6. India oncology NGS: Application Estimates & Trend Analysis

Chapter 7. India oncology NGS: Workflow Estimates & Trend Analysis

Chapter 8. India oncology NGS: End-Use Estimates & Trend Analysis

Chapter 9 Competitive Landscape

List of Tables

List of Figures